Healthcare Industry News: metabolic disease
News Release - May 18, 2011
Molecular Response Appoints Kenna Anderes, PhD, as Senior Vice President of Translational MedicineSAN DIEGO--(Healthcare Sales & Marketing Network)-- Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the appointment of Kenna L. Anderes, PhD, as senior vice president of translational medicine.
“Dr. Anderes’ background and leadership experience will be a great addition to our efforts of providing precision medicine at Molecular Response,” said Cyrus Mirsaidi. “Kenna is an accomplished leader who is known for her ability to guide multidisciplinary teams by leveraging target validation, mechanism of action, biomarker and co-diagnostic tools to ensure scientific validation.”
Dr. Anderes brings 20 years experience with research and development in cancer, cardiovascular and metabolic disease. Prior to joining Molecular Response, she held an executive leadership role at Cylene Pharmaceuticals where she managed the successful progression of proprietary oncology-focused programs through discovery and into clinical development. Dr. Anderes held several group leader and senior scientist positions at major pharmaceutical and biotech companies such as Pfizer, Warner Lambert, Agouron and Alanex for more than 12 years.
“I am delighted about the opportunity to work with an organization that is truly committed to the focus of providing personalized medicine,” said Dr. Anderes. “Research and clinical scientists recognize the limitations of cell line studies and have embraced the movement to conduct preclinical research in primary cells derived from cancer patients. The results obtained from patient tumor samples bring us one step closer to understanding the molecular basis of the cancer and creates the opportunity to customize molecular targeted therapy.”
Dr. Anderes earned a BS in microbiology from the University of Illinois and a PhD in Pharmacology from the Southern Illinois University School of Medicine. She was awarded a postdoctoral research fellowship in pharmacology at the University of California San Diego.
About Molecular Response
Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.
For additional information please visit www.molecularresponse.com.
Source: Molecular Response
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.